A review of an investigational drug retatrutide, a novel triple agonist agent for the treatment of obesity
The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.
Abstract
Background Obesity is one of the critical public health problems in our society. It leads to various health conditions, such as type 2 diabetes mellitus, cardiovascular disease, hypertension, dyslipidaemia, and non-alcoholic fatty liver disease. With the rising incidence of obesity, there is a growing demand for new therapies which can effectively manage body weight and improve health. Current evidence Currently under development, multi-receptor agonist drugs may offer a promising solution to meet this unmet medical need. Retatrutide is a novel triple receptor agonist peptide that targets the glucagon receptor (GCGR), glucose-dependent insulinotropic polypeptide receptor (GIPR), and glucagon-like peptide-1 receptor (GLP-1R). This novel drug has the potential to treat metabolic abnormalities associated with obesity as well as diseases resulting from it due to its distinct mechanism of action. The Phase III trial of this pipeline drug for treating type 2 diabetes mellitus, non-alcoholic fatty liver disease, and obesity started on August 28, 2023. The results of a Phase II clinical trial have demonstrated significant weight reduction in overweight and obese adults. Specifically, the trial reported an average weight loss of 17.5% and 24.4% at 24 and 48 weeks, respectively. Conclusions These findings hold promise for the development of effective weight loss interventions in this population group. There is a need for more phase III studies to provide sufficient clinical evidence fo…
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“However, activating multiple receptors may lead to more complex side effects, and in some experiments, dual and triple agonists have indeed shown more severe side effects.165,166”
From Glucagon-like peptide-1 receptor: mechanisms and advances in therapy (2024) · cites this paper as [165]
In the citing paper
“Retatrutide combines appetite suppression (GLP-1, GIP) with increased energy expenditure via glucagon receptor stimulation. This multifaceted mechanism targets both caloric intake and energy metabolism and enhances insulin secretion, optimizes glucose homeostasis, and effectively regulates appetite [70].”
From Obesity: Clinical Impact, Pathophysiology, Complications, and Modern Innovations in Therapeutic Strategies (2025) · cites this paper as [70]
Citations
Cites
Biology of Incretins: GLP-1 and GIP
Baggio, L. L., & Drucker, D. J. (2007) · Gastroenterology · doi:10.1053/j.gastro.2007.03.054 · Cited by 3,639 · cited 2×
“It also encourages the glucose-induced production of insulin, which replenishes the reserves of insulin in beta cells [11–13].”
Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1
Drucker, D. J. (2018) · Cell Metabolism · doi:10.1016/j.cmet.2018.03.001 · Cited by 2,170 · cited 1×
“…to directly activating brain regions that the molecule can reach, GLP-1 receptors may also affect neuronal activity in other brain regions, such as the lateral parabrachial nucleus, that are involved in the regulation of appetite, food intake, food preference, reward, and meal termination [19–22].”
Glucagon-like peptide 1 (GLP-1)
Müller, T. D., Finan, B., Bloom, S. R., D'Alessio, D., Drucker, D. J., Flatt, P. R., Fritsche, A., Gribble, F., Grill, H. J., Habener, J. F., et al. (2019) · Molecular Metabolism · doi:10.1016/j.molmet.2019.09.010 · Cited by 1,868 · cited 1×
“Because of this complex interaction, the satiating effects of exogenous GLP-1 when given intraperitoneally require an intact vagus nerve but not when given intravenously [17, 18].”
Triple-Hormone-Receptor Agonist Retatrutide for Obesity — A Phase 2 Trial
Jastreboff, A. M., Kaplan, L. M., Frías, J. P., Wu, Q., Du, Y., Gurbuz, S., Coskun, T., Haupt, A., Milicevic, Z., & Hartman, M. L. (2023) · New England Journal of Medicine · doi:10.1056/nejmoa2301972 · Cited by 1,174
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161 · cited 1×
“GIP is quickly broken down by DPP-4 to create the inactive GIP (3–42) metabolite [25].”
Coskun, T., Sloop, K. W., Loghin, C., Alsina-Fernandez, J., Urva, S., Bokvist, K. B., Cui, X., Briere, D. A., Cabrera, O., Roell, W. C., et al. (2018) · Molecular Metabolism · doi:10.1016/j.molmet.2018.09.009 · Cited by 882 · cited 3×
“The drug’s (0.1 nmol/kg) effect on glucose decrease in wild-type mice during an ipGTT demonstrated this, since it maintained an ED50 similar to the tripeptide’s (0.2 nmol/kg) [33].”
InfluentialGIP and GLP-1, the two incretin hormones: Similarities and differences
Seino, Y., Fukushima, M., & Yabe, D. (2010) · Journal of Diabetes Investigation · doi:10.1111/j.2040-1124.2010.00022.x · Cited by 746 · cited 1×
“Modulation of feeding has been associated with GIPR expression in the hypothalamus, namely, in the dorsomedial, paraventricular, and arcuate nuclei—three hypothalamic regions related to energy balance [26, 27].”
Semaglutide lowers body weight in rodents via distributed neural pathways.
Gabery, S., Salinas, C. G., Paulsen, S. J., Ahnfelt-Rønne, J., Alanentalo, T., Baquero, A. F., Buckley, S. T., Farkas, E., Fekete, C., Frederiksen, K. S., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.133429 · Cited by 717
Mechanisms of action of glucagon-like peptide 1 in the pancreas
Doyle, M. E., & Egan, J. M. (2007) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2006.11.007 · Cited by 680
Tirzepatide is an imbalanced and biased dual GIP and GLP-1 receptor agonist
Willard, F. S., Douros, J. D., Gabe, M. B. N., Showalter, A. D., Wainscott, D. B., Suter, T. M., Capozzi, M. E., van der Velden, W. J. C., Stutsman, C., Cardona, G. R., et al. (2020) · JCI Insight · doi:10.1172/jci.insight.140532 · Cited by 541 · cited 1×
“CAMP research evaluated the effectiveness and potency of drugs using low receptor-density clonal cell lines, which provided accurate and little signal pathway amplification [30].”
Research works printed but not linked: 2
- Purnell JQ (2000) Definitions, Classification, and Epidemiology of Obesity. In: Feingold KR, Anawalt B, Blackman MR et al (eds) Endotext [Internet]. MDText.com, Inc., South Dartmouth (MA). https://www.ncbi.nlm.nih.gov/books/NBK279167/
- Chaudharya M, Sharma P (2023) Abdominal obesity in India: analysis of the National Family Health Survey-5 (2019–2021) data. Lancet 14:1–10
Cited by
Glucagon-like peptide-1 receptor: mechanisms and advances in therapy
Zheng, Z., Zong, Y., Ma, Y., Tian, Y., Pang, Y., Zhang, C., & Gao, J. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01931-z · Cited by 1,036
“158,161,164,165 However, activating multiple receptors may lead to more complex side effects, and in some experiments, dual and triple agonists have indeed shown more severe side effects.”
BackgroundAdvance in peptide-based drug development: delivery platforms, therapeutics and vaccines
Xiao, W., Jiang, W., Chen, Z., Huang, Y., Mao, J., Zheng, W., Hu, Y., & Shi, J. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-02107-5 · Cited by 449
GLP-1 receptor agonists in patients with chronic kidney disease and either overweight or obesity
Abasheva, D., Ortíz, A., & Fernández‐Fernández, B. (2024) · Clinical Kidney Journal · doi:10.1093/ckj/sfae296 · Cited by 70
Ullah, M. I., & Tamanna, S. (2025) · Medicines · doi:10.3390/medicines12030019 · Cited by 38
“This multifaceted mechanism targets both caloric intake and energy metabolism and enhances insulin secretion, optimizes glucose homeostasis, and effectively regulates appetite [70].”
Structural insights into the triple agonism at GLP-1R, GIPR and GCGR manifested by retatrutide
Li, W., Zhou, Q., Cong, Z., Yuan, Q., Li, W., Zhao, F., Xu, H. E., Zhao, L.-H., Yang, D., & Wang, M.-W. (2024) · Cell Discovery · doi:10.1038/s41421-024-00700-0 · Cited by 32
The power of three: Retatrutide’s role in modern obesity and diabetes therapy
Abdul-Rahman, T., Roy, P., Ahmed, F. K., Mueller-Gomez, J. L., Sarkar, S., Garg, N., Femi-Lawal, V. O., Wireko, A. A., Thaalibi, H. I., Hashmi, M. U., et al. (2024) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2024.177095 · Cited by 27
Semaglutide: a key medication for managing cardiovascular-kidney-metabolic syndrome
MacIsaac, R. J. (2025) · Future Cardiology · doi:10.1080/14796678.2025.2511412 · Cited by 30
Jalil, J., Gabrielli, L., Ocaranza, M. P., MacNab, P., Fernández, R., Grassi, B. A., Jofré, P., Verdejo, H., Acevedo, M., Córdova, S., et al. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25084407 · Cited by 28
Endocrine and metabolic effects of GLP-1 receptor agonists on women with PCOS, a narrative review
Monney, M., Mavromati, M., Leboulleux, S., & Gariani, K. (2025) · Endocrine Connections · doi:10.1530/ec-24-0529 · Cited by 30
“However, future data speci fi c to PCOS are still needed (78).”
Sinha, B., & Ghosal, S. (2025) · Obesity · doi:10.1002/oby.24360 · Cited by 31
Lymperopoulos, A., Borges, J. I., & Stoicovy, R. A. (2024) · Pharmaceutics · doi:10.3390/pharmaceutics16060693 · Cited by 23
“Retatrutide is another “multi-agonist”, structurally similar to tirzepatide, which activates the glucagon receptor in addition to the GLP-1R and the GIPR [25].”
BackgroundKaur, M., & Misra, S. (2024) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2024-0065 · Cited by 18
Self-citationGruzmark, F. S., Beraja, G. E., Jozic, I., & Lev‐Tov, H. A. (2025) · Wound Repair and Regeneration · doi:10.1111/wrr.70085 · Cited by 17
“Phase 2 data from Retatrutide clinical trials have shown promising results in terms of weight reduction and glycemic control [143, 144].”
Yan, K., Yu, H., & Blaise, B. (2025) · Acta Diabetologica · doi:10.1007/s00592-025-02534-y · Cited by 20
“Third, there is limited supporting data on GIP-targeting Retatrutide provided additional benefits through glucagon receptor activation [22 ], the differences in weight loss and glycemic control between Retatrutide and Tirzepatide were not significant.”
Liu, L., Rashid, M., & Wess, J. (2025) · Biochemistry · doi:10.1021/acs.biochem.4c00867 · Cited by 16
Concepción‐Zavaleta, M. J., Fuentes‐Mendoza, J. M., Yovera, J. G. G., Ruvalcaba-Barbosa, G. Y., Cura-Rodríguez, L. D., González-Rodríguez, J. S., Urteaga, L. A. C., Pérez-Reyes, A. I., Aldave, J. E. Q., & Paz‐Ibarra, J. (2025) · World Journal of Gastroenterology · doi:10.3748/wjg.v31.i37.111435 · Cited by 17
“Ongoing phase 3 trials are expected to provide crucial data on its impact on advanced fibrosis and cirrhosis, and potential regulatory submissions are anticipated within the next few years[74,75].”
Cazac, G.-D., Lăcătușu, C.-M., Grigorescu, E.-D., Foșălău, A.-B., Onofriescu, A., & Mihai, B. M. (2025) · Journal of Clinical Medicine · doi:10.3390/jcm14041042 · Cited by 10
“Retatrutide also improved some MASH biomarkers, such as K-18 and Pro-C3 [111,112].”
Recent advances, strategies, and future perspectives of peptide-based drugs in clinical applications
Yang, Q., Hu, Z., Jiang, H., Wang, J., Han, H., Shi, W., & Qian, H. (2025) · Chinese Journal of Natural Medicines · doi:10.1016/s1875-5364(25)60800-4 · Cited by 20
Kim, S.-E., & Yoo, B. (2025) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2024.387 · Cited by 5
“Retatrutide is a triple GIP/GLP-1/glucagon receptor agonist [109].”
Li, Q., Cheng, W., Zhang, L., Ran, S., Yu, H., Zhou, W., Wang, Y., Lin, J., Liu, Y., Hong, X., et al. (2026) · Diabetology & Metabolic Syndrome · doi:10.1186/s13098-026-02116-0 · Cited by 5
“Crucially, the dramatic weight loss induced by Reta-trutide must be underpinned by a substantial reduction in adipose mass [16, 17].”
Maryam, M., Varghese, T. P., Tazneem, B., & Reddy, G. R. (2025) · American Journal of Cardiovascular Drugs · doi:10.1007/s40256-025-00735-y · Cited by 5
“…and cardiovascular risk factors, including weight loss, decreased waist circumference, decreased lipid levels, and blood pressure reduction [31] [31] • Semaglutide: A GLP-1 RA officially authorized for chronic weight management, semaglutide has been shown to produce significant weight loss…”
Currently Approved and Future Regimens for Metabolic Dysfunction-Associated Steatohepatitis
Abreu, E. S., Noureddin, M., Takahashi, H., Schattenberg, J. M., & Abdelmalek, M. F. (2026) · Clinics in Liver Disease · doi:10.1016/j.cld.2026.01.004 · Cited by 4
Ahmed, I. S., Tapponi, S. L., Manaa, H. M., Soltani, A., Hussein, E. S., Parvaresh, F. A., & Hussain, Z. (2026) · Journal of Obesity · doi:10.1155/jobe/6556057 · Cited by 5
The Role of the Gastroenterologist in Obesity Management: Now Is the Right Time for Our Involvement
Gold, S. L., & Kornbluth, A. A. (2024) · The American Journal of Gastroenterology · doi:10.14309/ajg.0000000000002791 · Cited by 8
“For example, retatrutide, known as the “ triple G, ” targets GLP-1, GIP, and glucagon, and has demonstrated weight loss up to 24% after 48 weeks of treatment in initial studies, surpassing the drugs on the market currently (23).”
BackgroundCan GLP-1RAs redefine transplantation standard of care?
Almalki, B. A. (2025) · Trends in Pharmacological Sciences · doi:10.1016/j.tips.2025.08.013 · Cited by 6
Windram, M., Lovelock, D. F., Carew, J. M., Krieman, C. G., Hendershot, C. S., & Besheer, J. (2025) · Psychopharmacology · doi:10.1007/s00213-025-06854-3 · Cited by 8
“…receptor agonists is thought to offer clinical advantages, potentially providing better tolerability or enhanced effectiveness due to simultaneous modulation of reward-related neural circuits and metabolic pathways (Ray 2023; Tufvesson-Alm et al. 2023; Badulescu et al. 2024; Kaur and Misra 2024).”
Zhou, C., Gong, B., Liu, X., Hu, G., & Sun, L. (2025) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2025.177681 · Cited by 2
Misra, S., Narayan, R. K., & Kaur, M. (2025) · Journal of Basic and Clinical Physiology and Pharmacology · doi:10.1515/jbcpp-2025-0113 · Cited by 3
Self-citationCurrent management of MASLD in type 2 diabetes
Fernández‐Garibay, V. M., Sarabia-Chao, V., & Chávez-Tapia, N. C. (2026) · HORMONES · doi:10.1007/s42000-026-00763-6 · Cited by 1
Santos, A. M. S., de Carvalho, C. J., Lopes, A. D. C. P., Ruas, S. K. J., Paseto, E. D., Arruda, L. V. M., & Colombari, J. P. C. (2024) · doi:10.22533/at.ed.46824120412
SÍFILIS CONGÊNITA: ASPECTOS EPIDEMIOLÓGICOS EM MARÍLIA-SP
Azevedo, G. B., & Rubira, C. J. (2024) · doi:10.22533/at.ed.46824120416
O NEUROPSICOPEDAGOGO NA EQUIPE MULTIDISCIPLINAR DE TRATAMENTO DA DEPENDÊNCIA QUÍMICA
Girolamo, F. D. F. F. P. P. D. (2024) · doi:10.22533/at.ed.46824120413
VESICULA BILIAR DUPLICADA: RELATO DE CASO
Sperotto, E. A., Urzagaste, C. H. V., Urzagaste, M. V., & Urzagaste, R. V. (2024) · doi:10.22533/at.ed.46824120418
Guerra, D. K. H., de Oliveira, V. G., da Silveira, I. C. B., Moreira, E. V. S., Filho, V. T. A. M., Neto, J. A., Braga, V., Portela, J. E. G., de Oliveira, A. A., de Sousa, M. B. M., et al. (2024) · doi:10.22533/at.ed.4682412041
FATORES QUE INFLUENCIAM O INICIO TARDIO DO PRÉ-NATAL
da Silva, A. V., de Carvalho, A. K. P., Neri, D. T., Pena, L. D., Joubert, P. P., Braga, V. D. S., & Gomes, V. R. (2024) · doi:10.22533/at.ed.4682412045
MENINGITES BACTERIANAS ASPECTOS INTRODUTORIOS E PROFILÁTICOS
Netto, F. D. F., Gehring, G. M., Mansani, F. P., Cordeiro, T. M. G., Benitez, J. G., Mayer, R., Machado, L. G. P., Gomes, R. Z., Derbli, E. S., Jecohti, V. M., et al. (2024) · doi:10.22533/at.ed.4682412049
Oliveira, A. C. B. C. D. C., Granja, C. E. L., de lírio, L. R., Bellegarde, K., Torres, L. C., Bispo, J. V., Cunha, F. A. G., Groke, M. J. Q., Cadamuro, M. D. P. D. R., Gomes, F. B. T., et al. (2024) · doi:10.22533/at.ed.4682412047
ESTIGMA E ACEITAÇÃO: EXPLORANDO AS DIMENSÕES SOCIAIS DO PÉ TORTO CONGÊNITO NA INFÂNCIA
Oliva, A. D. O., Rosa, P. C. G., Furlan, J. B., Bueno, N. S., Alssuffi, J. E. A., Figueiredo, E. V., de Castro, G. G., Becegatto, T. F., Silva, A. L. B., Cavalcante, F. R. P., et al. (2024) · doi:10.22533/at.ed.4682412044
RETATRUTIDA NO TRATAMENTO DA OBESIDADE: AVALIAÇÃO DA EFICÁCIA E EVIDÊNCIAS CLÍNICAS
Guerra, D. K. H., Amâncio, S. A., Figueiredo, A. D. S., Coutinho, C. C. C., Moreira, E. V. S., Aguiar, G. B. C., Coelho, J. M., Barbosa, L. G., de Melo, M. C. S., Guimarães, R. V., et al. (2024) · doi:10.22533/at.ed.46824120415
Jornada médica: desafios e triunfos na prática da medicina 5
Neto, B. R. D. S. (2024) · doi:10.22533/at.ed.468241204
MORBIDADE HOSPITALAR DO SUS POR AFECÇÕES PROSTÁTICAS NO PERÍODO DE 2020 A 2021 EM FORTALEZA, CE
Ponte, R. M. A., de Oliveira, A. A., Carneiro, A. G. A., Coutinho, C. C. C., da Silva, C. W. F., Neto, F. H. D. S., Coelho, J. M., Neto, J. A., Feitosa, L. A. M., Costa, M. P., et al. (2024) · doi:10.22533/at.ed.46824120410
MUDANÇA DE AUTODETERMINAÇÃO DE GÊNERO EM PACIENTE EM EPISÓDIO PSICÓTICO MANIFORME: RELATO DE CASO
Gonçalves, L. F. C., Casquer, M. S., Welter, P. M. G., & Freire, S. D. (2024) · doi:10.22533/at.ed.46824120411
Ponte, R. M. A., de Oliveira, A. A., de Sousa, A. F., Fitaroni, A. C. V. A. M., Gomes, D. R. P., Teixeira, I. C., Caetano, J. V. D. M., Coelho, J. M., Fales, L. T. D. C. C., Silva, P. V. T. S., et al. (2024) · doi:10.22533/at.ed.4682412042
ESPIRITUALIDADE NOS CUIDADOS PALIATIVOS EM PACIENTES PEDIÁTRICOS: UMA REVISÃO DE LITERATURA
Amâncio, L. D. M. F., Moreira, L. D. C., de Souza, L. K. C., Ferreira, K. C., Novaes, B. H. G. D. S., Maciel, G. R., de Sousa, I. S., Miranda, Y. R. V., Figueiredo, L. P. L. R., Silva, C. M. D. M., et al. (2024) · doi:10.22533/at.ed.4682412043
do Amaral, M. V. F., Urzagaste, C. H. V., Guerra, E. E., Urzagaste, R. V., & Urzagaste, M. V. (2024) · doi:10.22533/at.ed.4682412046
Megiani, I. N., Peruche, P. R. C. M., Freitas, R. C. D. O., Moura, M. D. P., Pereira, J. V. G., Vidal, V. M. D. S., Serrano, L. C., & da Silva, A. P. (2024) · doi:10.22533/at.ed.4682412048 · Cited by 1
USO DE PLATAFORMAS DIGITAIS PARA FACILITAR RELACIONAMENTOS AFETIVO-SEXUAIS NA PANDEMIA DA COVID-19
Oliveira, E. M., Faustino, D. C. F., de Souza, G. L. B., Suto, C. S. S., Bampi, L. N. D. S., Pegoraro, V. A., Coelho, H. T., Fontana, T. B., & de Almeida, S. R. (2024) · doi:10.22533/at.ed.46824120417
Ciarloni, A., Salvio, G., Bordoni, M., Giacchetti, G., & Balercia, G. (2026) · Biomedicines · doi:10.3390/biomedicines14040778
“In our opinion, a promising treatment option is represented by the combination of energy expenditure deriving from glucagon agonists like retatrutide [114] or survodutide [54] and increased LBM [129] obtainable with bimagrumab [130].”
InfluentialXiong, N., Mi, L., Wang, X., Zhang, T., Zhang, G., Chen, Y., Mo, D., Peng, J., Yao, H., Li, S., et al. (2026) · European Journal of Pharmacology · doi:10.1016/j.ejphar.2026.178942
Argano, C., Maggio, D., Pollicino, C., Cangialosi, V., Manno, S. B., Orlando, V., Monti, M. L., Grutta, A., Torres, A., & Corrao, S. (2026) · Frontiers in Pharmacology · doi:10.3389/fphar.2026.1784959
“Retatrutide (LY3437943) is a unimolecular peptide agonist of the GIPR, GLP-1R, and glucagon receptor, developed to exploit the complementary actions of these pathways (Kaur and Misra, 2024).”
Metadata
- Authors
- Kaur, M., & Misra, S.
- Affiliations
- Kalpana Chawla Government Medical College and Hospital (IN)
- Corresponding author
- Misra, Saurav
- ORCID
- Misra, Saurav
- Venue
- European Journal of Clinical Pharmacology
- Published
- 2024-02-17
- Volume
- 80
- Issue
- 5
- Pages
- 669-676
- ISSN
- 0031-6970 (ISSN-L)
- 1432-1041
- OpenAlex
- W4391899493
- Cited by
- 51
- References
- 35
- Citations by year
- 2026: 7 · 2025: 17 · 2024: 27
- FWCI
- 3.18
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springernature.com/gp/researchers/text-and-data-mining (tdm)
- www.springernature.com/gp/researchers/text-and-data-mining (vor)
- Locations
- European Journal of Clinical Pharmacology (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Pharmacology (medical) › Pharmacology and Obesity Treatment
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Keywords
- retatrutide, obesity, glucagon receptor, glucose-dependent insulinotropic polypeptide receptor, GLP-1 receptor, weight loss, type 2 diabetes, non-alcoholic fatty liver disease, investigational drugs, drug safety and efficacy
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Glucagon-Like Peptide-1 Receptor Agonists, Diabetes Mellitus, Type 2, Humans, Obesity, Weight Loss, Drugs, Investigational, Non-alcoholic Fatty Liver Disease
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.